Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy

Amyloid

Volumn 24, Issue 4, 2017, Pages 219-225

  Benson, Merrill D ^a,b   Dasgupta, Noel R ^a   Rissing, Stacy M ^a   Smith, Jessica ^a   Feigenbaum, Harvey ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Amyloidosis; cardiomyopathy; heart failure; transthyretin

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; PREALBUMIN;

ADULT; AGED; ARTICLE; ATTR AMYLOIDOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DESIGN; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE WALL; HEART MUSCLE BIOPSY; HOSPITAL ADMISSION; HUMAN; MALE; MIDDLE AGED; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTRICTIVE CARDIOMYOPATHY; SINGLE BLIND PROCEDURE; SIX MINUTE WALK TEST; ANTAGONISTS AND INHIBITORS; CARDIOMYOPATHY; CLINICAL TRIAL; DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY; FAMILIAL AMYLOID POLYNEUROPATHY; GENETICS; METABOLISM; PATHOPHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID NEUROPATHIES, FAMILIAL; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; PREALBUMIN; RNA, MESSENGER;

EID: 85029515037     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.1080/13506129.2017.1374946     Document Type: Article

References (19)

1. Benson MD., Amyloidosis. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular bases of inherited disease, Part 22 connective tissue. 8th ed. Vol IV. Chapter 209. New York (NY): McGraw Hill Book Co; 2001. p. 5345–5378.
2. Benson MD, Kincaid JC., The molecular biology and clinical features of amyloid neuropathy [Invited Review]. Muscle Nerve. 2007;36:411–423.
3. Westermark P, Sletten K, Johansson B, et al. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA. 1990;87:2843–2845.
4. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120:1203–1212.
5. Benson MD, Teague SD, Kovacs R, et al. Rate of progression of transthyretin amyloidosis. Am J Cardiol. 2011;108:285–289.
6. Benson MD, Kluve-Beckerman B, Zeldenrust SR, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve. 2006;33:609–618.
7. Ackermann EJ, Guo S, Benson MD, et al. Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides. Amyloid. 2016;23:148–157.
8. Lang RM, Badano LP, Mor-Avi V, et al. recommendations for cardiac chamber quantification by echochardiography in adults: an update for the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1–39.
9. Kristen AV, Siepen FAD, Scherer K, et al. Comparison of different types of cardiac amyloidosis by cardiac magnetic resonance imaging. Amyloid. 2015;22:132–141.
10. Ericzon B-G, Wilczek H, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99:1847–1854.
11. Suhr OB, Larsson M, Ericzon B-G, et al. Survival after transplantation in patients with mutations other than Val30Met: Extracts from the FAP World Transplant Registry. Transplantation. 2016;100:373–381.
12. Benson MD., Liver transplantation and transthyretin amyloidosis [Invited Review]. Muscle Nerve. 2013;47:157–162.
13. Nelson LM, Penninga L, Sander K, et al. Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy. Clin Transplant. 2013; 27:203–209.
14. Davis MK, Kale P, Liedtke M, et al. Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. Am J Transplant. 2015;15:650–658.
15. Falk RH, Quarta CC., Short-term progression of LV dysfunction in senile cardiac amyloidosis detected consistently by Doppler speckle tracking. JACC. 2012;59:E1562.
16. Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68:1014–1020.
17. Ruberg F, Maurer MS, Judge DP, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;164:222–228.
18. Pinney JH, Whelan CJ, Petrie A, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013;2:1–11.
19. Connors LH, Sam F, Skinner M, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation. 2016;133:282–290.